CAR-T treatment trial for relapsed or hard-to-treat blood cancers
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial studies whether a CAR-T cell therapy is safe and effective for people with relapsed or refractory lymphoma, leukemia, or myeloma whose tumors have the right target markers. You may qualify if your health (heart, lungs, kidneys, liver) and blood counts are within required limits.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have lymphoma, leukemia, or myeloma that has come back or is not responding to treatment
- Your tumor must have specific target markers for CAR-T, confirmed by a lab test (flow cytometry or tissue staining)
- You are between 14 and 75 years old, and you can have any gender
- You must be well enough to participate (performance status score of 0 to 2) and have enough blood function (hemoglobin at least 70 g/L)
- Your heart, lung, kidney, and liver test results must be within safe limits (including heart pumping function ≥50% and oxygen levels >90%)
- You cannot have certain exclusions like uncontrolled serious infection, active hepatitis, HIV, or previous CAR-T/gene-modified cell therapy
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new CAR-T cell therapy for people with certain blood cancers (B-cell acute lymphoblastic leukemia, B-cell lymphoma, or multiple myeloma) that have come back or stopped responding to treatment. The therapy uses your own immune cells, modified in a lab to attack cancer cells, then given back to you intravenously.
This trial tests a new type of immune cell therapy (CAR-T cells) designed to fight blood cancers that have come back or stopped responding to standard treatments. The therapy uses your own immune cells, which are modified in a lab to better recognize and attack cancer cells.
This trial tests a new treatment using specially modified immune cells (CAR-T cells) to fight certain blood cancers that have come back or haven't improved with standard treatments. It may help your body's own immune system attack the cancer cells.
This study tests a personalized cell treatment called CAR-T for people whose blood cancer (like lymphoma, leukemia, or chronic lymphocytic leukemia) has come back or not gotten better after standard treatment. The therapy uses your own immune cells, modified in a lab, to find and fight the cancer.
This trial tests a new treatment called CAR-T cell therapy that uses your own immune cells to fight cancer. It is for people with multiple myeloma or plasma cell leukemia that has come back or not responded to other treatments.
This trial tests whether CAR-T cells, a type of immunotherapy that targets specific markers on cancer cells, can treat blood cancers that have come back or not responded to standard treatment. It may offer a new option for people with lymphoma, leukemia, or multiple myeloma.
Hear when a new Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.